Aspirin more effective with Plavix in AF

31 March 2009

Plavix (clopidogrel), marketed by respective French and US drug majors Sanofi-Aventis and Bristol-Myers Squibb, is more effective when combined  with aspirin, than the latter alone in preventing major vascular events  in patients with atrial fibrilation who cannot take oral anticoagulants,  according to the ACTIVE A the trial presented at the annual scientific  session of the American College of Cardiology.

ACTIVE A was a Phase III, double-blind, placebo-controlled trial  designed to compare the combination of Plavix 75mg once daily plus  aspirin to aspirin alone  for preventing the first occurrence of a major  vascular event. The study included 7,554 patients with atrial  fibrillation who could not take OACs and had at least one major risk  factor for stroke.

Findings demonstrated that Plavix plus aspirin significantly reduced  major vascular events by 11% over aspirin alone, at a median of 3.6  years of follow-up (6.8% versus 7.6% per year, p=0.01). The greatest  benefit was seen in the reduction of stroke, by 28% (2.4% vs 3.3% per  year, p<0.001). Other components of major vascular events, such as  non-central nervous system systemic embolism, heart attack or vascular  death, did not reach statistical significance. Compared to aspirin  alone, taking Plavix in addition significantly increased the rate of  major bleeding (2.0% vs 1.3% per year, p < 0.001).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight